Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?

Overview

Journal J Investig Med

Publisher Sage Publications

Specialty General Medicine

Date 2020 Jul 24

PMID 32699179

Citations 15

Authors

Allison Bethanne Reiss

Amy D Glass

Thomas Wisniewski

Benjamin Wolozin

Irving H Gomolin

Aaron Pinkhasov

Joshua De Leon

Mark M Stecker

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a neurodegenerative brain disorder associated with relentlessly progressive cognitive impairment and memory loss. AD pathology proceeds for decades before cognitive deficits become clinically apparent, opening a window for preventative therapy. Imbalance of clearance and buildup of amyloid β and phosphorylated tau proteins in the central nervous system is believed to contribute to AD pathogenesis. However, multiple clinical trials of treatments aimed at averting accumulation of these proteins have yielded little success, and there is still no disease-modifying intervention. Here, we discuss current knowledge of AD pathology and treatment with an emphasis on emerging biomarkers and treatment strategies.

Citing Articles

A Look at the Etiology of Alzheimer's Disease based on the Brain Ischemia Model.

Pluta R Curr Alzheimer Res. 2024; 21(3):166-182.

PMID: 38963100 DOI: 10.2174/0115672050320921240627050736.

Improving preclinical to clinical translation of cognitive function for aging-related disorders: the utility of comprehensive touchscreen testing batteries in common marmosets.

Murai T, Bailey L, Schultz L, Mongeau L, DeSana A, Silva A Cogn Affect Behav Neurosci. 2024; 24(2):325-348.

PMID: 38200282 PMC: 11039501. DOI: 10.3758/s13415-023-01144-x.

Amyloid-β Effects on Peripheral Nerve: A New Model System.

Stecker M, Srivastava A, Reiss A Int J Mol Sci. 2023; 24(19).

PMID: 37833938 PMC: 10572603. DOI: 10.3390/ijms241914488.

Localized proteomic differences in the choroid plexus of Alzheimer's disease and epilepsy patients.

Leitner D, Kanshin E, Faustin A, Thierry M, Friedman D, Devore S Front Neurol. 2023; 14:1221775.

PMID: 37521285 PMC: 10379643. DOI: 10.3389/fneur.2023.1221775.

Alzheimer's Disease Treatment: The Search for a Breakthrough.

Reiss A, Muhieddine D, Jacob B, Mesbah M, Pinkhasov A, Gomolin I Medicina (Kaunas). 2023; 59(6).

PMID: 37374288 PMC: 10302500. DOI: 10.3390/medicina59061084.

References

Rivera-Escalera F, Pinney J, Owlett L, Ahmed H, Thakar J, Olschowka J . IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia. J Neuroinflammation. 2019; 16(1):261. PMC: 6902486. DOI: 10.1186/s12974-019-1645-7. View

Drummond E, Wisniewski T . Alzheimer's disease: experimental models and reality. Acta Neuropathol. 2016; 133(2):155-175. PMC: 5253109. DOI: 10.1007/s00401-016-1662-x. View

Du X, Wang X, Geng M . Alzheimer's disease hypothesis and related therapies. Transl Neurodegener. 2018; 7:2. PMC: 5789526. DOI: 10.1186/s40035-018-0107-y. View

Mathews P, Levy E . Exosome Production Is Key to Neuronal Endosomal Pathway Integrity in Neurodegenerative Diseases. Front Neurosci. 2020; 13:1347. PMC: 6920185. DOI: 10.3389/fnins.2019.01347. View

Cao F, Liu Z, Sun G . Diagnostic value of miR-193a-3p in Alzheimer's disease and miR-193a-3p attenuates amyloid-β induced neurotoxicity by targeting PTEN. Exp Gerontol. 2019; 130:110814. DOI: 10.1016/j.exger.2019.110814. View

Sabri O, Sabbagh M, Seibyl J, Barthel H, Akatsu H, Ouchi Y . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015; 11(8):964-74. DOI: 10.1016/j.jalz.2015.02.004. View

Jang H, Park J, Woo S, Kim S, Kim H, Na D . Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. Neuroimage Clin. 2019; 24:101941. PMC: 6677900. DOI: 10.1016/j.nicl.2019.101941. View

Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O . Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017; 52:196-213. DOI: 10.1016/j.neurobiolaging.2016.02.034. View

Huang L, Chao S, Hu C . Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020; 27(1):18. PMC: 6943903. DOI: 10.1186/s12929-019-0609-7. View

10.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

11.

Shepherd T, Nayak G . Clinical Use of Integrated Positron Emission Tomography-Magnetic Resonance Imaging for Dementia Patients. Top Magn Reson Imaging. 2019; 28(6):299-310. DOI: 10.1097/RMR.0000000000000225. View

12.

Arvanitakis Z, Shah R, Bennett D . Diagnosis and Management of Dementia: Review. JAMA. 2019; 322(16):1589-1599. PMC: 7462122. DOI: 10.1001/jama.2019.4782. View

13.

Penney J, Ralvenius W, Tsai L . Modeling Alzheimer's disease with iPSC-derived brain cells. Mol Psychiatry. 2019; 25(1):148-167. PMC: 6906186. DOI: 10.1038/s41380-019-0468-3. View

14.

Hussain I, Powell D, Howlett D, Tew D, Meek T, Chapman C . Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999; 14(6):419-27. DOI: 10.1006/mcne.1999.0811. View

15.

Malone E, Oliva M, Sabatini P, Stockley T, Siu L . Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1):8. PMC: 6961404. DOI: 10.1186/s13073-019-0703-1. View

16.

Dehghani R, Rahmani F, Rezaei N . MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms. Rev Neurosci. 2017; 29(2):161-182. DOI: 10.1515/revneuro-2017-0042. View

17.

Joe E, Ringman J . Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ. 2019; 367:l6217. DOI: 10.1136/bmj.l6217. View

18.

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

19.

Imbimbo B, Watling M . Investigational BACE inhibitors for the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2019; 28(11):967-975. DOI: 10.1080/13543784.2019.1683160. View

20.

Wimo A, Winblad B, Jonsson L . The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement. 2010; 6(2):98-103. DOI: 10.1016/j.jalz.2010.01.010. View